Hematology Diagnostics Market — By Product, By Test Type, By Modality, By Application, By End Use — Global Forecast, 2025 to 2034

Hematology Diagnostics Market Size

The global hematology diagnostics market size was valued at USD 7.5 billion in 2024 and is expected to exhibit growth at a CAGR of 5.2% from 2025 to 2034 period. The high market growth can be attributed to the rising prevalence of hematological disorders, growing aging population and chronic diseases, and technological advancements in diagnostics, among other contributing factors.
 

Moreover, the increasing prevalence of blood disorders, including anemia, leukemia, lymphoma, and sickle cell anemia, is driving the demand for advanced hematology diagnostics. For instance, according to the World Health Organization (WHO), in 2022, around 1.28 billion people globally were affected by anemia, with women and children being the most vulnerable groups. Similarly, the Centers for Disease Control and Prevention (CDC) estimated that sickle cell disease affects approximately 100,000 Americans as of 2023. The need for early and accurate diagnosis to ensure effective treatment has increased the adoption of hematology analyzers and diagnostic tools.
 

Furthermore, innovations in hematology diagnostic equipment, such as automated hematology analyzers, flow cytometers, and point-of-care testing devices, enhance accuracy, speed, and convenience. These advancements are encouraging their adoption across hospitals, clinics, and diagnostic laboratories.
 

Hematology diagnostics refers to the field of medical testing that focuses on analyzing blood, blood-forming organs, and associated disorders. It involves the use of specialized instruments, reagents, and techniques to detect abnormalities in blood components such as red and white blood cells, platelets, hemoglobin, and clotting factors.
 

Hematology Diagnostics Market Trends

The market is witnessing significant growth driven by continuous innovations in hematology diagnostics, surging demand for artificial intelligence in healthcare and machine learning, and rising adoption of flow cytometry, among other factors are boosting the industry growth.
 

• Further, the adoption of automated hematology analyzers and systems is increasing, driven by their ability to deliver faster, more accurate, and reproducible results. Automation minimizes manual errors, enhances workflow efficiency, and enables high-throughput testing in diagnostic laboratories.
   
• Moreover, the rising demand for point-of-care hematology testing devices is transforming the market. These compact, portable devices provide rapid diagnostic results at or near the patient’s location, making them ideal for emergency settings, remote areas, and home healthcare, thereby driving market growth.
   

Hematology Diagnostics Market Analysis

Based on product, the market is classified into reagents and consumables and instruments. The instruments segment is further bifurcated into hematology analyzers, flow cytometers, and other instruments. The reagents and consumables segment generated the highest revenue of USD 4.9 billion in 2024.
 

• Advancements in automated hematology analyzers have increased the demand for high-quality reagents and consumables. These reagents are crucial for maintaining optimal functionality and ensuring accurate test results, especially in high-throughput clinical settings, driving consistent demand.
   
• Furthermore, reagents and consumables are recurring purchases, as they need to be replenished after each set of diagnostic tests. Hospitals, laboratories, and diagnostic centers require continuous supplies to maintain operations, ensuring a stable market for these products.
   

Based on test type, the hematology diagnostics market is classified into complete blood count (CBC) test, platelet function test, hemoglobin test, hematocrit test, and other test types. The complete blood count (CBC) test segment accounted for USD 2.7 billion revenue in 2024 and is anticipated to grow at a CAGR of 4.5% between 2025 to 2034 period.
 

• CBC is a standard and widely used test in routine health check-ups and preventive healthcare. Its ability to provide a comprehensive snapshot of a patient's overall health including red and white blood cell counts, hemoglobin levels, and platelet counts contributes to its frequent use in early disease detection.
   
• Moreover, the test is relatively low cost and widely accessible, making it a preferred diagnostic tool for healthcare providers. Its affordability and simplicity make it a first-line test for diagnosing various conditions, from infections to blood cancers, driving its demand in hospitals and clinics. These advantages are expected to fuel growth in this segment of the market.
   

Based on modality, the hematology diagnostics market is classified into laboratory-based testing and point-of-care (POC) testing. The laboratory-based testing segment dominated the market in 2024 with a market share of 67%.
 

• Laboratory-based testing offers higher accuracy and reliability compared to other diagnostic methods. Advanced equipment, such as automated analyzers, ensures precise results, making laboratory testing the preferred choice for diagnosing complex blood disorders like anemia, leukemia, and other hematological conditions.
   
• Furthermore, it has the capability to conduct a wide range of hematology tests, including complete blood count, blood smears, and specialized tests for detecting blood cancers and other hematological abnormalities. The ability to perform detailed and comprehensive testing drives the demand for laboratory-based diagnostics.
   

Based on application, the hematology diagnostics market is classified into oncology, anemia, infectious diseases, cardiovascular disorders, and other applications. The oncology segment accounted for USD 2.6 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 4.8% between 2025 to 2034 period.
 

• The increasing incidence of hematological cancers, including leukemia, lymphoma, and myeloma, drives growth in the oncology segment of hematology diagnostics. According to the American Cancer Society, in 2024, approximately 70,135 new cases of non-Hodgkin lymphoma, 24,810 cases of multiple myeloma, and 62,270 new cases of leukemia are expected in the U.S. Blood tests enable early detection of these cancers, which is essential for treatment effectiveness, thus increasing the demand for advanced diagnostic tools.
   
• Moreover, the growing trend of personalized medicine in oncology, which tailors treatment based on the genetic profile of tumors, relies heavily on hematology diagnostic tests. Techniques like genetic sequencing and biomarker testing are essential for identifying specific mutations and predicting responses to targeted therapies, thereby fueling the demand for sophisticated diagnostic technologies in oncology.
   

Based on end use, the hematology diagnostics market is segmented into hospitals, diagnostic laboratories, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 6.6 billion by the end of the forecast period.
 

• Hospitals are seeing a growing number of patients with hematological disorders, including anemia, leukemia, and other blood-related conditions. This rise in patient volume creates a higher demand for efficient and accurate hematology diagnostic tools to handle a large number of tests and diagnoses.
   
• Moreover, with the growing trend toward personalized medicine, hospitals are investing in hematology diagnostic tools that can provide more precise, individualized results. Personalized treatment plans based on comprehensive diagnostic data require hospitals to adopt advanced hematology diagnostic instruments.
   

U.S. hematology diagnostics market accounted for USD 2.9 billion market revenue in 2024 and is anticipated to grow at a CAGR of 4.8% between 2025 to 2034 period.
 

• The U.S. has a large population diagnosed with hematological disorders, including anemia, leukemia, and sickle cell disease. For instance, as per the National Cancer Institute, around 60,650 new cases of leukemia were diagnosed in 2022. This high prevalence of disease drives the demand for advanced diagnostic tools in hospitals and clinical laboratories to ensure accurate and timely diagnoses.
   
• Furthermore, the country allocates a significant portion of its GDP to healthcare, which supports the continued expansion and improvement of diagnostic infrastructure. Hospitals and clinics are increasingly adopting advanced hematology diagnostic devices to meet the growing demand for high-quality healthcare and reduce patient care costs by providing quicker, more accurate diagnoses, thereby contributing to market growth.
   

Germany hematology diagnostics market is projected to grow remarkably in the coming years.
 

• Germany is known for its advanced healthcare infrastructure and high medical standards. Hospitals and diagnostic centers are well-equipped with state-of-the-art hematology diagnostic instruments, driving the demand for advanced technologies.
   
• The German healthcare system provides robust reimbursement policies for diagnostic services, including hematology tests. This support reduces financial barriers for healthcare providers, encouraging them to adopt the latest hematology diagnostic instruments and technologies to ensure high-quality patient care.
   

Japan holds a dominant position in the Asia Pacific hematology diagnostics market.
 

• The rising incidence of cancer cases in Japan, particularly hematological cancers like leukemia and lymphoma, is driving the demand for specialized hematology diagnostic tools. According to the Japanese National Cancer Center, in 2021, approximately 13,000 new cases of leukemia and 33,000 cases of lymphoma were reported.
   
• The Ministry of Health, Labor and Welfare reported that blood cancer cases increased by 8% in 2022 compared to the previous year, with an estimated 48,000 new cases in 2023. The need for effective monitoring and treatment of blood cancers is supporting the growth of the market.
   

Hematology Diagnostics Market Share

The market is highly competitive, with several key players dominating the landscape. Major companies, such as Abbott, Roche, Siemens Healthineers, Beckman Coulter, and Sysmex, lead the market with innovative hematology analyzers and diagnostic solutions. These players focus on technological advancements, such as automation and integration with AI, to enhance diagnostic accuracy and speed. Additionally, competition is fueled by continuous product development, mergers, acquisitions, and partnerships to expand market reach and improve clinical outcomes in hematology diagnostics.
 

Hematology Diagnostics Market Companies

Prominent players operating in the hematology diagnostics industry include:

• Abbott
• BAG DIAGNOSTICS
• BECKMAN COULTER
• BIO-RAD
• BioSystems
• Boule
• diatron
• HemoCue
• HORIBA Medical
• mindray
• NIHON KOHDEN
• Roche
• SIEMENS Healthineers
• sysmex
• Thermo Fisher Scientific
   

Hematology Diagnostics Industry News:

• In January 2024, HORIBA Medical has launched the HELO 2.0 high-throughput automated hematology platform, CE-IVDR approved with pending US FDA approval. Designed in consultation with customers, this new generation platform offers a flexible, scalable solution for mid to large-scale laboratories, improving efficiency and meeting the needs of fully automated hematology testing.
   
• In January 2021, F. Hoffmann-La Roche Ltd. announced a strategic partnership with Sysmex Corporation for the distribution of Sysmex hematology products, including instruments and reagents. Additionally, Roche is committed to supporting improvements in hematology testing for the diagnosis and treatment of various blood disorders. This strategic partnership has helped the company enhance its market presence and expand its customer base.
   

The hematology diagnostics market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Reagents and consumables
• Instruments
  • Hematology analyzers
  • Flow cytometers
  • Other instruments

Market, By Test Type

• Complete blood count (CBC) test
• Platelet function test
• Hemoglobin test
• Hematocrit test
• Other test types

Market, By Modality

• Laboratory-based testing
• Point-of-care (POC) testing

Market, By Application

• Oncology
• Anemia
• Infectious diseases
• Cardiovascular disorders
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE